SC
VKTX icon

Steven Cohen’s Viking Therapeutics VKTX Stock Holding History

Steven Cohen’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$390K Buy
+10,000
New +$323K ﹤0.01% 3285
2018
Q4 		– Sell
-150,000
Closed -$2.61M – 1221
2018
Q3 		$2.61M Buy
+150,000
New +$1.78M 0.01% 723

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Steven Cohen's VKTX Position: Q2 2026 in Review

Steven Cohen opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 473,308 shares worth $18.5M. The stake represents 0.02% of the portfolio and ranks #935 among its holdings. This is a return to the name: Steven Cohen previously reported a position in VKTX as recently as Q4 2025.

Steven Cohen first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Steven Cohen held 473,308 shares of Viking Therapeutics worth $18.5M as of Q2 2026.
  • Viking Therapeutics was a new Steven Cohen position in Q2 2026.
  • Viking Therapeutics made up 0.02% of Steven Cohen's portfolio in Q2 2026, its #935 holding.
  • Steven Cohen first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.